24-May-2024
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
Seeking Alpha News (Sat, 25-May 10:24 AM ET)
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 9-May 7:15 AM ET)
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
Globe Newswire (Thu, 9-May 7:00 AM ET)
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
Globe Newswire (Thu, 2-May 2:00 AM ET)
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
Globe Newswire (Thu, 25-Apr 2:00 AM ET)
Andrew Fisher Joins Verona Pharma as General Counsel
Globe Newswire (Mon, 4-Mar 2:00 AM ET)
Globe Newswire (Thu, 29-Feb 2:00 AM ET)
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Business Wire (Tue, 27-Feb 7:00 AM ET)
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Verona Pharma PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol VRNA.
As of May 24, 2024, VRNA stock price climbed to $12.04 with 408,637 million shares trading.
VRNA has a beta of 1.16, meaning it tends to be more sensitive to market movements. VRNA has a correlation of 0.08 to the broad based SPY ETF.
VRNA has a market cap of $976.22 million. This is considered a Small Cap stock.
In the last 3 years, VRNA stock traded as high as $26.44 and as low as $3.41.
The top ETF exchange traded funds that VRNA belongs to (by Net Assets): IBB, SBIO, GWX, ONEQ, GINN.
VRNA has underperformed the market in the last year with a price return of -44.9% while the SPY ETF gained +30.4%. VRNA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -27.0% and -18.9%, respectively, while the SPY returned +4.6% and +1.7%, respectively.
VRNA support price is $11.60 and resistance is $12.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRNA stock will trade within this expected range on the day.